Report Sections

See All Reports

  • HP:0007354: Amyotrophic lateral sclerosis
  • Pneumonia (359) Respiratory tract infection (38) Neoplasm (36) Abnormality of the cardiovascular system (34) Diabetes mellitus (33) Depressivity (29) Acute kidney injury (27) Hypoxemia (26) Hypertension (24) Abnormal lung morphology (24) Thromboembolism (22) Anosmia (20) Myocardial infarction (20) Arthritis (19) Type II diabetes mellitus (18) Stroke (16) Pulmonary embolism (16) Mental deterioration (15) Abnormality of coagulation (15) Pulmonary fibrosis (15) Chronic pulmonary obstruction (15) Abnormality of the kidney (14) Autistic behavior (14) Rheumatoid arthritis (14) Leukemia (14) Interstitial pneumonitis (14) Pulmonary obstruction (14) Asthma (13) Chronic pain (13) Congestive heart failure (12) Deep venous thrombosis (12) Neoplasm of the lung (12) Autism (11) Obesity (11) Respiratory distress (11) Colitis (11) Ulcerative colitis (11) Crohn's disease (11) Type I diabetes mellitus (10) Abnormality of the liver (9) Coronary artery atherosclerosis (9) Inflammation of the large intestine (9) Pulmonary insufficiency (9) Chronic kidney disease (9) Myocarditis (9) Behavioral abnormality (8) Psychosis (8) Dementia (8) Alzheimer disease (8) Carcinoma (8) Low levels of vitamin D (8) Sepsis (8) Infertility (7) Peripheral arterial stenosis (7) Renal insufficiency (6) Lymphopenia (6) Dysphagia (6) Lymphoma (6) Systemic lupus erythematosus (6) Osteoarthritis (6) Breast carcinoma (6) Psoriasiform dermatitis (6) Abnormality of the gastrointestinal tract (6) Fatigue (6) Encephalopathy (5) Premature birth (5) Bronchiectasis (5) Difficulty walking (5) Gastroparesis (5) Immunodeficiency (5) Obstructive sleep apnea (5) Autoimmunity (5) Knee osteoarthritis (5) Sleep apnea (5) Prostate cancer (5) Allergy (5) Non-small cell lung carcinoma (5) Schizophrenia (5) Neoplasm of the large intestine (5) Seizure (4) Hepatic fibrosis (4) Cardiac arrest (4) Weight loss (4) Migraine (4) Pulmonary arterial hypertension (4) Abnormal intestine morphology (4) Neoplasm of the pancreas (4) Colon cancer (4) Malnutrition (4) Paroxysmal atrial fibrillation (4) Disseminated intravascular coagulation (4) Attention deficit hyperactivity disorder (4) Inflammatory abnormality of the skin (4) Neoplasm of head and neck (4) Endometriosis (4) Addictive behavior (4) Hypercoagulability (4) Insomnia (4) Obsessive-compulsive behavior (3) Eczema (3) Atopic dermatitis (3) Spastic diplegia (3) Abnormal heart morphology (3) Cardiomyopathy (3) Fever (3) Hypothermia (3) Headache (3) Celiac disease (3) Reduced factor VIII activity (3) Lymphoid leukemia (3) Renal cell carcinoma (3) Abnormal anterior horn cell morphology (3) Amyotrophic lateral sclerosis (3) Cystoid macular edema (3) Arrhythmia (3) Cutaneous melanoma (3) Pulmonary edema (3) Ovarian neoplasm (3) Neuroendocrine neoplasm (3) Hypogeusia (2) Hearing impairment (2) Abnormality of the eye (2) Visual impairment (2) Conjunctivitis (2) Cataract (2) Uveitis (2) Agoraphobia (2) Abnormality of the endocrine system (2) Abnormality of the skin (2) Jaundice (2) Lymphedema (2) Spasticity (2) Meningitis (2) Abnormal joint morphology (2) Hepatic steatosis (2) Hepatic failure (2) Tachycardia (2) Angina pectoris (2) Pancreatitis (2) Abnormality of blood and blood-forming tissues (2) Thrombocytopenia (2) Autoimmune thrombocytopenia (2) Gout (2) Diarrhea (2) Gastroesophageal reflux (2) Apnea (2) Neurodegeneration (2) Alopecia of scalp (2) Mutism (2) Transient ischemic attack (2) Hyperkinetic movements (2) Polyphagia (2) Hypotension (2) Atherosclerosis (2) Hypoventilation (2) Squamous cell carcinoma (2) Myelodysplasia (2) Back pain (2) Low back pain (2) Muscular dystrophy (2) Stillbirth (2) Acute myeloid leukemia (2) Lymphoproliferative disorder (2) Myeloproliferative disorder (2) Multiple myeloma (2) Intervertebral disc degeneration (2) Stridor (2) Postprandial hyperglycemia (2) Hemeralopia (2) Arteritis (2) Hepatitis (2) Glioblastoma multiforme (2) Cervix cancer (2) Small cell lung carcinoma (2) Endocarditis (2) Toxemia of pregnancy (2) Myositis (2) Mania (2) Urinary retention (1) Urinary incontinence (1) Nephritis (1) Menorrhagia (1) Xerostomia (1) Otitis media (1) Conductive hearing impairment (1) Amblyopia (1) Periodontitis (1) IgA deposition in the glomerulus (1) Enuresis (1) Hypoparathyroidism (1) Adrenal insufficiency (1) Hyperaldosteronism (1) Osteopenia (1) Urticaria (1) Angiokeratoma corporis diffusum (1) Cholecystitis (1) Keratoconjunctivitis (1) Intellectual disability (1) Hemiparesis (1) Polyneuropathy (1) Syncope (1) Cerebral hemorrhage (1) Hepatocellular carcinoma (1) Intrauterine growth retardation (1) Hoarse voice (1) Dysphonia (1) Weak voice (1) Sudden cardiac death (1) Aortic valve stenosis (1) Bradycardia (1) Torsade de pointes (1) Atrioventricular block (1) Premature rupture of membranes (1) Dehydration (1) Constipation (1) Anorexia (1) Esophageal varix (1) Chorea (1) Status epilepticus (1) Subarachnoid hemorrhage (1) Abnormality of the spinal cord (1) Memory impairment (1) Encephalitis (1) Spina bifida (1) Language impairment (1) Waddling gait (1) Increased intracranial pressure (1) Biliary cirrhosis (1) Dilatation (1) Osteomyelitis (1) Central apnea (1) Hypokalemia (1) Hyponatremia (1) Hyperphosphatemia (1) Skeletal muscle atrophy (1) Male infertility (1) Spondylolisthesis (1) Myalgia (1) Bruxism (1) Neonatal death (1) Increased body weight (1) Intermittent claudication (1) Thrombophlebitis (1) Chronic bronchitis (1) Ventricular tachycardia (1) Acute myelomonocytic leukemia (1) Dilatation of the cerebral artery (1) Coronary artery stenosis (1) Venous insufficiency (1) Chronic lymphatic leukemia (1) Abnormality of bone marrow cell morphology (1) Hypersensitivity pneumonitis (1) Intraalveolar phospholipid accumulation (1) Neoplasm of the genitourinary tract (1) Neoplasm of the skin (1) Female infertility (1) Benign prostatic hyperplasia (1) Hip osteoarthritis (1) Bladder neoplasm (1) Stomatitis (1) Uterine neoplasm (1) Intestinal atresia (1) Placental abruption (1) Sinus tachycardia (1) Bronchiolitis (1) Erythroid hypoplasia (1) Asterixis (1) Hodgkin lymphoma (1) B-cell lymphoma (1) Ciliary dyskinesia (1) Myeloid leukemia (1) Chronic myelomonocytic leukemia (1) Morphea (1) Bronchitis (1) Hypercapnia (1) Pain (1) Retinal vein occlusion (1) Vasovagal syncope (1) Heart block (1) Cough (1) Neonatal asphyxia (1) Dyspareunia (1) Heart murmur (1) Cardiogenic shock (1) Cholangitis (1) Cholangiocarcinoma (1) Vulvar neoplasm (1) Neonatal sepsis (1) Glue ear (1) Abnormality of movement (1) Subdural hemorrhage (1) Biliary tract neoplasm (1) Nasal polyposis (1) Eclampsia (1) Esophagitis (1) Vaginal neoplasm (1) Cellulitis (1) Angioedema (1) Self-injurious behavior (1) Gastrointestinal stroma tumor (1) Bulimia (1) Neoplasm of the rectum (1) Chest pain (1) Atelectasis (1) Lymphocytosis (1) Polymenorrhea (1)

    HP:0007354: Amyotrophic lateral sclerosis

    Developed by Shray Alag, The Harker School
    Sections: Correlations, Clinical Trials, and HPO

    Correlations computed by analyzing all clinical trials.

    Navigate: Clinical Trials and HPO

    Correlated Drug Terms (6)

    Name (Synonyms) Correlation
    drug494 BNT162b3 Wiki 0.58
    drug480 BLZ945 Wiki 0.58
    drug844 Cannabis, Medical Wiki 0.58
    Name (Synonyms) Correlation
    drug493 BNT162b2 Wiki 0.33
    drug492 BNT162b1 Wiki 0.33
    drug2916 Placebo Wiki 0.05

    Correlated MeSH Terms (26)

    Name (Synonyms) Correlation
    D000690 Amyotrophic Lateral Sclerosis NIH 1.00
    D016472 Motor Neuron Disease NIH 1.00
    D000070627 Chronic Traumatic Encephalopathy NIH 0.58
    Name (Synonyms) Correlation
    D005879 Tourette Syndrome NIH 0.58
    D001714 Bipolar Disorder NIH 0.41
    D012598 Scoliosi NIH 0.40
    D012640 Seizures NIH 0.33
    D000755 Anemia, Sickle Cell NIH 0.29
    D005356 Fibromyalgia NIH 0.26
    D001927 Brain Diseases NIH 0.26
    D000070642 Brain Injuries, Traumatic NIH 0.19
    D010300 Parkinsonian NIH 0.19
    D015212 Inflammatory Bowel Diseases NIH 0.19
    D003424 Crohn Disease NIH 0.17
    D001930 Brain Injuries, NIH 0.16
    D059350 Chronic Pain NIH 0.16
    D009103 Multiple Sclerosis NIH 0.14
    D040921 Stress Disorders, Traumatic NIH 0.10
    D014947 Wounds and Injuries NIH 0.10
    D013313 Stress Disorders, Post-Traumatic NIH 0.10
    D004194 Disease NIH 0.09
    D013577 Syndrome NIH 0.05
    D003141 Communicable Diseases NIH 0.04
    D007239 Infection NIH 0.03
    D045169 Severe Acute Respiratory Syndrome NIH 0.02
    D018352 Coronavirus Infections NIH 0.02

    Correlated HPO Terms (7)

    Name (Synonyms) Correlation
    HP:0006802 Abnormal anterior horn cell morphology HPO 1.00
    HP:0100754 Mania HPO 0.41
    HP:0001250 Seizure HPO 0.29
    Name (Synonyms) Correlation
    HP:0001298 Encephalopathy HPO 0.26
    HP:0002037 Inflammation of the large intestine HPO 0.19
    HP:0100280 Crohn's disease HPO 0.17
    HP:0012532 Chronic pain HPO 0.16

    Clinical Trials

    Navigate: Correlations   HPO

    There are 3 clinical trials

    1 Outcomes Mandate National Integration With Cannabis as Medicine for Prevention and Treatment of COVID-19

    This will be a multistate, multicenter clinical study to determine the efficacy and safety of medical cannabis for a wide variety of chronic medical conditions.

    1. Chronic Pain
    2. Chronic Pain Syndrome
    3. Chronic Pain Due to Injury
    4. Chronic Pain Due to Trauma
    5. Fibromyalgia
    6. Seizures
    7. Hepatitis C
    8. Cancer
    9. Crohn Disease
    10. HIV/AIDS
    11. Multiple Sclerosis
    12. Traumatic Brain Injury
    13. Sickle Cell Disease
    14. Post Traumatic Stress Disorder
    15. Tourette Syndrome
    16. Ulcerative Colitis
    17. Glaucoma
    18. Epilepsy
    19. Inflammatory Bowel Diseases
    20. Parkinson Disease
    21. Amyotrophic Lateral Sclerosis
    22. Chronic Traumatic Encephalopathy
    23. Anxiety
    24. Depression
    25. Insomnia
    26. Autism
    27. Opioid-use Disorder
    28. Bipolar Disorder
    29. Covid19
    30. SARS-CoV Infection
    31. COVID-19
    32. Corona Virus Infection
    33. Coronavirus
    1. Drug: Cannabis, Medical
    MeSH:Infection Communicable Diseases Coronavirus Infections Severe Acute Respiratory Syndrome Fibromyalgia Crohn Disease Inflammatory Bowel Diseases Parkinson Disease Multiple Sclerosis Brain Injuries Brain Injuries, Traumatic Seizures Motor Neuron Disease Amyotrophic Lateral Sclerosis Brain Diseases Tourette Syndrome Chronic Traumatic Encephalopathy Anemia, Sickle Cell Disease Syndrome Sclerosis Chronic Pain Wounds and Injuries Stress Disorders, Traumatic Bipolar Disorder Stress Disorders, Post-Traumatic
    HPO:Abnormal anterior horn cell morphology Amyotrophic lateral sclerosis Bilateral tonic-clonic seizure Bipolar affective disorder Chronic pain Crohn's disease Encephalopathy Focal-onset seizure Generalized-onset seizure Inflammation of the large intestine Mania Seizure

    Primary Outcomes

    Description: Covid-19 infection rates in cannabis users will be compared to rates in the general population. Our online questionnaire responses will compare infection rates of cannabis users in this study against the Johns Hopkins University Coronavirus Research Center data (

    Measure: Prevention of COVID-19

    Time: Five years

    Description: Severity of persistent symptoms in cannabis users testing positive for active infection and/or antibodies will also be compared to the general population. Patients will answer the widely used FLU-PRO questionnaire, which asks about flu symptoms and severity, to capture diagnoses, symptoms, and medical interventions related to COVID-19. The data from cannabis user patients will be compared with national and international data surveys, such as the Covid Symptom Study (

    Measure: Treatment of COVID-19

    Time: Five years

    Description: The primary objective is to assess the efficacy and safety of medical cannabis as medicine for treatment of chronic pain and other chronic debilitating diseases. Pain will be measured by Brief Pain Inventory (BPI) numeric scale. Change from baseline in BPI will be assessed at 3-month intervals. For prospective associations between cannabis use and outcomes, use of a lagged mixed-effects models will examine temporal associations between cannabis use and pain severity, opioid sparing, and patient satisfaction. Data will be analyzed from baseline and the annual follow-up waves.

    Measure: Treatment of Symptoms

    Time: Five years

    Secondary Outcomes

    Description: Secondary objectives include evaluating increases or decreases in quality of life, and increases or decreases in concomitant opioid use. Satisfaction with treatment will be measured by a Visual Analog Score (VAS). Change From baseline in Satisfaction with treatment measured by (VAS) be assessed at 3-month intervals.

    Measure: Cannabis Impact on Quality of Life

    Time: Five years

    Description: Tertiary objectives will examine preferences for routes of administration, and preferences for THC / CBD ratios. Categorical factors will be summarized using frequencies and percentages, while continuous measure distributions will be described using means, standard deviations, and quartiles of interest.

    Measure: Cannabis Route and Dosing

    Time: Five years

    Description: Incidence of Treatment-Related Adverse Events will be measured by Physician Global Assessment (PGA) numeric scale. Number of participants with Treatment-Related Adverse Events will be assessed by CTCAE v4.0.

    Measure: Monitoring Adverse Events

    Time: Five years
    2 An Open-label, Adaptive Design Study in Patients With Amyotrophic Lateral Sclerosis (ALS) to Characterize Safety, Tolerability and Brain Microglia Response, as Measured by TSPO Binding, Following Multiple Doses of BLZ945 Using Positron Emission Tomography (PET) With the Radioligand [11C]-PBR28

    It is an open label study to evaluate safety, tolerability and brain microglia response in participants with ALS following multiple doses of BLZ945.

    1. Amyotrophic Lateral Sclerosis
    1. Drug: BLZ945
    MeSH:Motor Neuron Disease Amyotrophic Lateral Sclerosis Sclerosis
    HPO:Abnormal anterior horn cell morphology Amyotrophic lateral sclerosis

    Primary Outcomes

    Description: Volume of distribution (Vt) in different brain regions for each [11C]-PBR28 PET scan, and change after BLZ945 treatment, compared to baseline. Evaluate brain microglial reduction, as measured by reduction in TSPO binding following oral doses of BLZ945 in ALS participants by using PET imaging with [11C]-PBR28.

    Measure: Change from baseline in volume of distribution (Vt) in different brain regions for [11C]-PBR28 PET scan

    Time: Day -42, up to Day 22

    Secondary Outcomes

    Description: Measured by Cmax - The maximum plasma concentration of BLZ945

    Measure: Plasma Pharmacokinetics (PK) of BLZ945 - Cmax

    Time: Day 1; up to Day 17

    Description: Measured by Tmax - Time to Reach the Maximum Concentration After Drug Administration of BLZ945

    Measure: Plasma Pharmacokinetics (PK) of BLZ945 - Tmax

    Time: Day 1; up to Day 17

    Description: Measured by AUC - Area under the curve of BLZ945

    Measure: Plasma Pharmacokinetics (PK) of BLZ945 - AUC

    Time: Day 1; up to Day 17

    Description: Measured by T1/2 - The elimination half-life of BLZ945

    Measure: Plasma Pharmacokinetics (PK) of BLZ945 - T1/2

    Time: Day 1; up to Day 17

    Description: Urine renal clearance (CLR) of BLZ945

    Measure: Renal Clearance (CLR) of BLZ945

    Time: Day 1; up to Day 7

    Description: To assess the CYP2C8 pharmacogenomic-pharmacokinetic relationship; CYP2C8 genotyping and BLZ945 plasma PK parameters

    Measure: CYP2C8 genotyping and BLZ945 plasma PK parameters

    Time: Day 1; up to Day 17
    3 COVID-19 Amyotrophic Lateral Sclerosis (ALS) Registry

    Amyotrophic lateral sclerosis (ALS) is a relentlessly progressive and fatal neurodegenerative disease characterized by progressive weakness involving limb, bulbar, and respiratory muscles.There is currently no information suggesting how COVID-19 affects patients diagnosed with amyotrophic lateral sclerosis (ALS). This is especially important as respiratory compromise is common in ALS patients and can complicate the clinical course as COVID-19 could lead to respiratory failure and need for intubation. We intend that this registry will guide our understanding of how COVID-19 affects patients with ALS.

    1. Covid19
    2. Amyotrophic Lateral Sclerosis
    MeSH:Motor Neuron Disease Amyotrophic Lateral Sclerosis Sclerosis
    HPO:Abnormal anterior horn cell morphology Amyotrophic lateral sclerosis

    Primary Outcomes

    Description: Assessed through outcomes reporting ranging from recovered infections to patient death reported in a patient facing registry.

    Measure: COVID-19 incidence and prevalence in the ALS population

    Time: Data will be collected through study completion, an average of 3 years

    HPO Nodes


    Data processed on September 26, 2020.

    An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

    Drug Reports   MeSH Reports   HPO Reports  


    4,180 reports on interventions/drugs


    691 reports on MeSH terms


    263 reports on HPO terms

    All Terms

    Alphabetical index of all Terms

    Google Colab

    Python example via Google Colab Notebook